[an error occurred while processing this directive]

Hereditas(Beijing) ›› 2021, Vol. 43 ›› Issue (1): 30-39.doi: 10.16288/j.yczz.20-315

• Review • Previous Articles     Next Articles

Lung microbiome mediates the progression from chronic obstructive pulmonary disease to lung cancer through inflammation

Yajie Wang, Shuangshuang Wu, Jiang Chu(), Xiangyang Kong()   

  1. Genetics and Pharmacogenomics Laboratory, Medical School, Kunming University of Science and Technology, Kunming 650500, China
  • Received:2020-11-24 Revised:2020-12-28 Online:2021-01-20 Published:2021-01-12
  • Contact: Chu Jiang,Kong Xiangyang E-mail:chujiang2015@126.com;kxy2772@yahoo.com
  • Supported by:
    Supported by Provincial Training Program of Kunming University of Science and Technology No(KKSY201660006)

Abstract:

Lung microbiome exists in the respiratory tract and parenchymal tissues. It mediates lung injury through a variety of mechanisms, including bacterial disturbance, metabolites, inflammatory response, immune response, and genotoxicity. Accumulating evidences suggest that changes in lung microbiome correlates with chronic obstructive pulmonary disease (COPD) and lung cancer, and the microbiome promotes the progression from COPD to lung cancer. In this review, we mainly introduce the impairment of the homeostasis of the lung microbiome and its inflammation that leads to COPD and lung cancer, then focus on how the microbiome mediates the progression from COPD to lung cancer through inflammatory response. The review may provide a new theoretical basis for clinical prevention, optimal treatment strategy and design of new drugs for COPD and lung cancer.

Key words: lung microbiome, chronic obstructive pulmonary disease, lung cancer, diversity, inflammation